Coeptis Therapeutics (NASDAQ:ZSQR) vs. Sangamo Therapeutics (NASDAQ:SGMO) Head to Head Analysis

Sangamo Therapeutics (NASDAQ:SGMO) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Earnings & Valuation

This table compares Sangamo Therapeutics and Coeptis Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55 million	0.78	-$122.93 million	($0.38)	-0.19
Coeptis Therapeutics	$1.36 million	181.90	-$11.92 million	($2.52)	-1.91

Coeptis Therapeutics has lower revenue, but higher earnings than Sangamo Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Sangamo Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500.

Profitability

This table compares Sangamo Therapeutics and Coeptis Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Analyst Ratings

This is a summary of recent ratings for Sangamo Therapeutics and Coeptis Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2	1	1	0	1.75
Coeptis Therapeutics	1	0	0	0	1.00

Sangamo Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Sangamo Therapeutics is more favorable than Coeptis Therapeutics.

Institutional & Insider Ownership

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 24.2% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Sangamo Therapeutics beats Coeptis Therapeutics on 9 of the 14 factors compared between the two stocks.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.